SCHEMBL7110432

SCHEMBL7110432

O=C(NCCOc1ccc2c(c1)[nH]c1ccccc12)OCc1ccccc1

nearest known ligand 0.60

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.60
MAPT P10636 1/20 0.60
CTSV O60911 3/20 0.57
CTSL P07711 3/20 0.57
LMNA P02545 1/20 0.54
SMN1; SMN2 Q16637 1/20 0.54
TRPM8 Q7Z2W7 1/20 0.46
HTT P42858 1/20 0.46
GABRA1 P14867 1/20 0.46
GABRG2 P18507 1/20 0.46
GABRB3 P28472 1/20 0.46
GABRA3 P34903 1/20 0.46
GABRA2 P47869 1/20 0.46
KDM4E B2RXH2 1/20 0.45
IMPDH2 P12268 1/20 0.43
GAA P10253 1/20 0.43
IDO1 P14902 1/20 0.43
TDO2 P48775 1/20 0.43
BMP1 P13497 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7254686 0.88 L3MBTL1 (0.53) L3MBTL1MAPTCTSVCTSLLMNA
SCHEMBL5195006 0.86 L3MBTL1 (0.57) L3MBTL1MAPTCTSVCTSLLMNA
SCHEMBL7106197 0.86 L3MBTL1 (0.53) L3MBTL1MAPTCTSVCTSLLMNA
SCHEMBL5197720 0.86 L3MBTL1 (0.59) L3MBTL1MAPTCTSVCTSLLMNA
SCHEMBL5193224 0.83 L3MBTL1 (0.56) L3MBTL1MAPTCTSVCTSLLMNA
SCHEMBL7967629 0.83 MAPT (0.55) L3MBTL1MAPTLMNASMN1; SMN2TRPM8
SCHEMBL7113244 0.81 LMNA (0.59) L3MBTL1CTSVCTSLLMNAKDM4E
SCHEMBL7108541 0.80 L3MBTL1 (0.60) L3MBTL1MAPTLMNASMN1; SMN2HTT
SCHEMBL7109712 0.80 L3MBTL1 (0.60) L3MBTL1MAPTLMNASMN1; SMN2TRPM8
SCHEMBL3811564 0.79 L3MBTL1 (0.80) L3MBTL1MAPTLMNASMN1; SMN2HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0882707-B1 NOVEL TRICYCLIC COMPOUNDS AND DRUG COMPOSITIONS CONTAINING THE SAME ASAHI CHEMICAL IND (JP) 2003-10-08 EP disclosed
US-20030139475-A1 Novel tricyclic compounds and drug compositions containing same ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) 2003-07-24 US disclosed
US-6545053-B1 Aminoethoxyfluorene derivatives are beta-3 adrenaline receptor agonists and are useful as drugs for the treatment and prevention of diabetes, obesity, hyperlipemia, etc. ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) 2003-04-08 US disclosed
US-6187809-B1 BETA-3 ADRENALINE RECEPTOR AGONIST DRUGS FOR THE TREATMENT OF DIABETES, OBESITY, AND HYPERLIPEMIA; 2-(N-(2-(DIBENZOFURAN-3-YLOXY)ETHYL)AMINO)-1-PHENYLETHANOL, FOR EXAMPLE ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) 2001-02-13 US disclosed
US-6037362-A CARBAZOLE DERIVATIVES; DEPROTECTING, AMINATION; ANTILIPEMIC AND ANTIDIABETIC AGENTS; B-ADRENALINE RECEPTOR AGONISTS; DIETETICS ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) 2000-03-14 US disclosed
EP-0882707-A1 NOVEL TRICYCLIC COMPOUNDS AND DRUG COMPOSITIONS CONTAINING THE SAME Asahi Kasei Kogyo Kabushiki Kaisha (JP) 1998-12-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030139475-A1 Novel tricyclic compounds and drug compositions containing same ADRB3, MC2R, NR3C1 L3MBTL1 2322/4885MAPT 4602/4885CTSV 4729/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.